# The Prevent Coronary Artery Disease Trial

Study · id `cardio:ct-nct06494501` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06494501](<https://clinicaltrials.gov/study/NCT06494501>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06494501

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1600 participants.

## Technical summary

Registry record NCT06494501. Randomized; no masking; primary purpose prevention. Start 2024-09-12 (actual); primary completion 2032-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1600 participants (planned count; ClinicalTrials.gov record NCT06494501, source copy `cardio:ctgov-nct06494501-2025-04-29`, retrieved 2026-10-31)
- Started: 2024-09-12 (actual) (ClinicalTrials.gov record NCT06494501, source copy `cardio:ctgov-nct06494501-2025-04-29`, retrieved 2026-10-31)
- Primary completion: 2032-06-30 (anticipated) (ClinicalTrials.gov record NCT06494501, source copy `cardio:ctgov-nct06494501-2025-04-29`, retrieved 2026-10-31)
- Completion: 2032-06-30 (anticipated) (ClinicalTrials.gov record NCT06494501, source copy `cardio:ctgov-nct06494501-2025-04-29`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT06494501, source copy `cardio:ctgov-nct06494501-2025-04-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06494501-2025-04-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Prevent Coronary Artery Disease Trial
- Acronym: PRECAD
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Inclisiran
- Lead sponsor: Icahn School of Medicine at Mount Sinai
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Icahn School of Medicine at Mount Sinai (`cardio:org-icahn-school-of-medicine-at-mount-sinai`)

## Provenance

Content hash: 2d1fb2fae699afe5062fa4dcd167f813eeea7c845befdd2b82447795a5a8a25a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
